The Ebola situation in Dallas—with one patient death, two nurse exposures, dozens under quarantine, and talk last week of declaring a state of emergency in the city—has thrown into stark relief the gaps between public health and frontline clinical care. But those gaps also present opportunities to make public health data work harder and to change how doctors approach clinical care in times when events and information are changing at Internet speed.
That’s the gist of an editorial by Boston Children’s Hospital’s Kenneth Mandl, MD, MPH, published Monday in the Journal of the American Medical Association.
It comes down to making electronic health records (EHRs) work more flexibly, in ways that help promote situational awareness among clinicians during times of crisis and flag instances when a patient’s condition may require more attention than usual. Full story »
Parents, clinicians, app developers, designers and more had 18 hours to prototype digital healthcare solutions at Hacking Pediatrics, produced by Boston Children’s Hospital and MIT Hacking Medicine. To accompany our earlier post, we created this Storify. Full story »
(Dana Hatic for MedTech Boston)
What are the pain points in pediatrics? There are at least 37: the number of clinicians, parents and others who lined up at the podium last weekend to pitch problems they hoped to solve
at the second annual Hacking Pediatrics.
The hackathon, produced by Boston Children’s Hospital in collaboration with MIT Hacking Medicine, brought out many common themes: Helping kids with chronic illnesses track their symptoms, take their meds and avoid lots of clinic visits. Helping parents coordinate their children’s care and locate resources. Helping pediatric clinicians make better decisions with the right information at the right time.
Hackathons have a simple formula: Pitch. Mix. Hack. Get Feedback. Iterate. Repeat—as many times as possible. Full story »
Where is the next generation of therapeutic innovations going to come from? Population-level genomic studies? The fitness trackers on everyone’s wrist? Mining electronic medical records? People’s tweets, Yelps and Facebook posts?
How about all of the above?
What all of these things have in common is data. Lots of it. Some of it represents kinds of data that didn’t exist 5 or 10 years ago, but all of it is slowly beginning to fuel the pharma sector’s efforts to create the next blockbuster drug or targeted therapeutic.
At least, it should be. Full story »
Health care institutions, universities and even the U.S. government are helping innovators hone their pitches and get backing.
On ABC’s reality show “Shark Tank
,” a panel of veteran investors listens to business pitches for everything from new dietary supplements to a nail salon for men. After asking tough questions, each shark either backs the venture—sometimes not for the reasons you’d think—or more likely declares, “I’m out.”
It’s a great infotainment formula—even my 10-year-old daughter is a fan—but it’s also a hit beyond the living room. Health care organizations are increasingly borrowing the “Shark Tank” script to get new ideas or to bankroll their own innovations. Boston Children’s Hospital is doing so at our Global Pediatric Innovation Summit + Awards (Oct. 30-31), bringing in “Shark Tank”’s Daymond John to moderate. But we’re certainly not alone. In recent months: Full story »
This winter, if your doctor suggests that you take Tamiflu, you might want to ask for a conflict of interest statement: a new study suggests that doctors who received payments from the makers of flu-fighting neuraminidase inhibitors—drugs like Tamiflu® and Relenza®—were more likely to view the drugs’ prowess in a favorable light.
In the study, published last week in the Annals of Internal Medicine, a team led by Boston Children’s Hospital’s Florence Bourgeois, MD, MPH, tallied up the financial connections of doctors who participated in 37 reviews of neuraminidase inhibitors.
While it’s been unclear for years whether these drugs really are effective against influenza, it was crystal clear that financial relationships are associated with positive reviews. Full story »
You are what you eat, the saying goes. For some conditions (think cardiovascular disease or type 2 diabetes), there are clear connections between diet, health and illness.
For breast cancer, the picture is less clear. Many epidemiologic and laboratory studies have examined the Western diet (in particular, cholesterol) and its relation to breast cancer, with conflicting results.
“There’s been a raging debate in the field,” says Christine Coticchia, PhD, who works in the laboratory of Boston Children’s Hospital’s Vascular Biology Program director, Marsha Moses, PhD. “The biology of cancer and of cholesterol are so complex, and there are many subsets of breast cancer. In order to find any connections, you have to ask very specific questions.”
Banding together with Keith Solomon, PhD, in Boston Children’s Urology Department, Coticchia and Moses asked whether dietary cholesterol might encourage progression of the most aggressive, so-called “triple-negative” breast tumors. As they report in the American Journal of Pathology, they found a big impact, at least in mice. But it’s too early to say just yet that cutting back on cholesterol will help women avoid breast cancer. Full story »
Through genetic engineering, this Vibrio cholerae biofilm can be loaded with extra antigens, creating a super-charged but inexpensive vaccine.
Malaria. Cholera. Now Ebola. Whatever the contagion, the need for new, or better, vaccines is a constant. For some of the most devastating public health epidemics, which often break out in resource-poor countries, vaccines have to be not only medically effective but also inexpensive. That means easy to produce, store and deliver.
Paula Watnick, MD, PhD, an infectious disease specialist at Boston Children’s Hospital, has a plan that stems from her work on cholera: using a substance produced by the bacteria themselves to make inexpensive and better vaccines against them.
Cells do all the work
Bacteria produce biofilms—a sticky, tough material composed of proteins, DNA and sugars—to help them attach to surfaces and survive. Full story »
Ivan Salgo, MD, MBA, is Senior Director, Cardiology, Philips Ultrasound.
I’m thrilled to be part of the judging panel for the Innovation Tank at Boston Children’s Hospital’s upcoming Global Pediatric Innovation Summit + Awards. I can’t imagine a better way to bring together a duly combustible mixture of new thoughts and ideas with the spark of innovation.
It’s very clear that the pace of innovation needs to accelerate.
The Innovation Tank provides a rich and engaging way to accelerate innovation by putting the best ideas and technologies in front of people who can incubate and fund them, and ultimately, take them to success.
The genius of the Innovation Tank is that it coalesces a critical mass of people and ideas in a single place. By bringing ideas to the front through competition, participants can raise the bar on their own creativity to bring forth compelling ideas that matter to medicine, that matter to peoples’ lives. Full story »
(Credit: Wyss Institute)
With the launch this summer of Emulate Inc., organs-on-chips—a disease-modeling platform we’ve covered several times on Vector—made the jump from academic to commercial development.
Though developed at the Wyss Institute for Biologically Inspired Engineering, the chips’ story actually began more than 20 years ago in Boston Children’s Hospital’s Vascular Biology Program (VBP). It’s a story that brings together characters from multiple fields and emerges from one fundamental concept: that mechanical forces are critical to the function and fate of cells, tissues and organs. Full story »